RESULTS OF TWO CASES WITH DISTINCT COMPLICATIONS DUE TO INTRAVITREAL BEVACIZUMAB IN RETINOPATHY OF PREMATURITY
Ozgur Yalcinbayir1,2, Gamze Ucan Gunduz1, Meral Yildiz1
1Department of Ophthalmology, Uludag University School of Medicine, Bursa, Turkey; and.
Purpose:
To present the surgical outcome and long-term follow-up of 2 cases who underwent intravitreal bevacizumab injection for retinopathy of prematurity (ROP) and subsequently developed full thickness macular hole and endophthalmitis.
Methods:
Case report.
Patients:
The first case is a premature girl who was delivered 650 g at the 27th week of postmenstrual age (PMA) because of preeclampsia and received intravitreal 0.16 mg bevacizumab bilaterally at the 38th PMA with the diagnosis of ROP. She was referred with endophthalmitis 10 days after injection in the left eye. Endophthalmitis resolved with pars plana vitrectomy that was performed the following day. The second case is a premature girl who was delivered at the 30th week of PMA weighing 1,230 g and received intravitreal 0.16 mg bevacizumab injections bilaterally at the 39th PMA with a diagnosis of ROP. Retinopathy of prematurity regressed in the follow-up; however, full thickness macular hole was noted in the right eye on the first week of the injection. Pars plana vitrectomy, internal limiting membrane peeling, and gas tamponade were performed at the 41st PMA week. Full thickness macular hole persisted despite pars plana vitrectomy whereas glaucoma emerged during the follow-up.
Conclusion:
Development of endophthalmitis and macular hole may occur after intravitreal injections in cases with ROP.
